Efficacy of intravenous gammaglobulin for immunoglobulin g subclass and/or antibody deficiency in adults

Nabih I. Abdou, Cindy A. Greenwell, Reena Mehta, Madhu Narra, Jeffery D. Hester, John F. Halsey

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy. Methods: We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated. Results: Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected. Conclusions: IgIV could be beneficial in patients with IgG subclass or antibody deficiency.

Original languageEnglish (US)
Pages (from-to)267-274
Number of pages8
JournalInternational Archives of Allergy and Immunology
Volume149
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

Intravenous Immunoglobulins
Immunoglobulin G
Antibodies
Innate Immunity
Infection
Quality of Life
Anti-Bacterial Agents
Mannose-Binding Lectin
Passive Immunization
Toll-Like Receptors
Tetanus
Respiratory Tract Infections
Hospitalization
Genotype
Guidelines
Incidence
Serum

Keywords

  • Antibody deficiency
  • Immunoglobulin G subclass
  • Intravenous gammaglobulin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Efficacy of intravenous gammaglobulin for immunoglobulin g subclass and/or antibody deficiency in adults. / Abdou, Nabih I.; Greenwell, Cindy A.; Mehta, Reena; Narra, Madhu; Hester, Jeffery D.; Halsey, John F.

In: International Archives of Allergy and Immunology, Vol. 149, No. 3, 06.2009, p. 267-274.

Research output: Contribution to journalArticle

Abdou, Nabih I. ; Greenwell, Cindy A. ; Mehta, Reena ; Narra, Madhu ; Hester, Jeffery D. ; Halsey, John F. / Efficacy of intravenous gammaglobulin for immunoglobulin g subclass and/or antibody deficiency in adults. In: International Archives of Allergy and Immunology. 2009 ; Vol. 149, No. 3. pp. 267-274.
@article{5b2e04a55788404c98c54e6b9deddeb4,
title = "Efficacy of intravenous gammaglobulin for immunoglobulin g subclass and/or antibody deficiency in adults",
abstract = "Background: The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy. Methods: We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated. Results: Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected. Conclusions: IgIV could be beneficial in patients with IgG subclass or antibody deficiency.",
keywords = "Antibody deficiency, Immunoglobulin G subclass, Intravenous gammaglobulin",
author = "Abdou, {Nabih I.} and Greenwell, {Cindy A.} and Reena Mehta and Madhu Narra and Hester, {Jeffery D.} and Halsey, {John F.}",
year = "2009",
month = "6",
doi = "10.1159/000199723",
language = "English (US)",
volume = "149",
pages = "267--274",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Efficacy of intravenous gammaglobulin for immunoglobulin g subclass and/or antibody deficiency in adults

AU - Abdou, Nabih I.

AU - Greenwell, Cindy A.

AU - Mehta, Reena

AU - Narra, Madhu

AU - Hester, Jeffery D.

AU - Halsey, John F.

PY - 2009/6

Y1 - 2009/6

N2 - Background: The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy. Methods: We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated. Results: Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected. Conclusions: IgIV could be beneficial in patients with IgG subclass or antibody deficiency.

AB - Background: The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy. Methods: We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated. Results: Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected. Conclusions: IgIV could be beneficial in patients with IgG subclass or antibody deficiency.

KW - Antibody deficiency

KW - Immunoglobulin G subclass

KW - Intravenous gammaglobulin

UR - http://www.scopus.com/inward/record.url?scp=59849090716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849090716&partnerID=8YFLogxK

U2 - 10.1159/000199723

DO - 10.1159/000199723

M3 - Article

VL - 149

SP - 267

EP - 274

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 3

ER -